Abstract
Objectives To examine the association between maternal depressive symptoms in the immediate postnatal period and offspring’s mental health in a large cohort of term- and preterm-born toddlers.
Design and Participants Data were drawn from the Developing Human Connectome Project. Maternal postnatal depressive symptoms were assessed at term, and children’s outcomes were evaluated at a median corrected age of 18.4 months (range 17.3 – 24.3).
Exposure and outcomes Preterm birth was defined as <37 weeks completed gestation. Maternal depressive symptoms were assessed with the Edinburgh Postnatal Depression Scale (EPDS). Toddlers’ outcome measures were parent-rated Child Behaviour Checklist 11/2-5 Total (CBCL) and Quantitative Checklist for Autism in Toddlers (Q-CHAT) scores. Toddlers’ cognition was assessed with the Bayley Scales of Infant and Toddler Development – Third Edition (Bayley-III).
Results Higher maternal EPDS scores were associated with toddlers’ higher CBCL (B=0.93, 95% CI 0.43-1.44, p<0.001, f2=0.05) and Q-CHAT scores (B=0.27, 95% CI 0.03-0.52, p=.031, f2=0.01). Higher maternal EPDS scores were not associated with toddlers’ cognitive outcomes. Maternal EPDS, toddlers’ CBCL and Q-CHAT scores did not differ between preterm (n=97; 19.1% of the total sample) and term participants.
Conclusions Our findings indicate that children whose mothers had increased depressive symptoms in the early postnatal period, including subclinical symptoms, exhibit more maternally-reported behavioural problems in toddlerhood. These associations were independent of gestational age. Further research is needed to confirm the clinical significance of these findings.
Strengths and limitations of this study
Prospective study with a large sample, using multiple imputation to reduce non-response bias.
Maternal depressive symptoms assessed as a continuous variable, providing more nuanced information about the significance of subclinical symptoms.
Maternal depressive symptoms assessed earlier than in previous studies, enabling recognition of early screening opportunities for families.
Potential shared method variance bias through parent-completed child behavioural assessments.
Unknown paternal and parental factors, such as comorbid psychiatric conditions, that may confound our findings.
Competing Interest Statement
Authors completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare financial and infrastructure support as outlined in the funding statement. ADE also received funding from the EU-AIMS-Trials (European Research Council under the European Union Seventh Framework Programme, co-Principal Investigator). ADE received consulting fees from Chiesi Farmaceutici (advice on neuroprotection in newborn infants) and Medtronix (unpaid participation in scientific advice committee). ADE has a patent: Xenon as an organ protectant (No P023708WO). ADE participated on the following Data Safety Monitoring Board or Advisory Boards: Baby-Oscar Trial (Chair of Data Monitoring and Ethics Committee), PAEN Trial (Data Monitoring and Ethics Committee). There are no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
The DHCP project was funded by the European Research Council under the European Union Seventh Framework Programme (FR/2007-2013)/ERC Grant Agreement no. 319456. The authors acknowledge infrastructure support from the National Institute for Health Research Mental Health Biomedical Research Centre at South London Maudsley NHS Foundation Trust, King's College London, and the National Institute for Health Research Mental Health Biomedical Research Centre at Guys and St Thomas' Hospitals NHS Foundation Trust. The study was also supported in part by the Engineering and Physical Sciences Research Council / Wellcome Trust Centre for Medical Engineering at King's College London (grant WT 203148/Z/16/Z) and the Medical Research Council (UK) (grants MR/K006355/1 and MR/L011530/1) and the MRC Centre for Neurodevelopmental Disorders at King's College London. AP receives a NIHR SI award (NF-SI-0617-10120). AL is supported by the UK Medical Research Council (MR/N013700) and King's College London member of the MRC Doctoral Training Partnership in Biomedical Sciences. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the UK National Research Ethics Authority (14/LO/1169) and conducted in accordance with the World Medical Association Code of Ethics (Declaration of Helsinki).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Research data will be available as part of Developing Human Connectome Project.
